<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">PBES</journal-id><journal-title-group><journal-title>Proceedings of Business and Economic Studies</journal-title></journal-title-group><issn>2209-2641</issn><eissn>2209-265X</eissn><publisher><publisher-name>Bio-Byword Scientific Publishing Pty. Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.26689/PBES.v9i10.16202</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>Practical Strategies for Patient Capital to Empower the Development of Sci-Tech Innovation Enterprises</title><url>https://artdesignp.com/journal/PBES/9/10/10.26689/PBES.v9i10.16202</url><author>ZhengWen</author><pub-date pub-type="publication-year"><year>2026</year></pub-date><volume>9</volume><issue>10</issue><history><date date-type="pub"><published-time>2026-11-16</published-time></date></history><abstract>Against the background of fostering new productive forces, patient capital serves as a critical financial force to ease financing constraints for sci‑tech innovation enterprises. Different from short‑term speculative capital, it features long holding cycles and risk‑sharing mechanisms, which can better match the long‑cycle R&amp;amp;D and high‑risk operational traits of hard‑tech firms. This paper sorts out the financing bottlenecks faced by domestic sci‑tech enterprises under traditional financing frameworks, such as maturity mismatch and insufficient qualified collateral. It further analyzes the adaptive logic between patient capital and innovative enterprises, and explores practical empowering paths from capital supply innovation, post‑investment value‑added services, and risk‑exit system optimization. Combined with relevant policy tools and ecological supporting conditions, this study puts forward targeted suggestions for expanding patient capital sources and improving supporting institutional arrangements. The findings can offer practical references for alleviating the financing pressure of sci‑tech enterprises and stimulating technological innovation vitality</abstract><keywords>Patient capital, Sci‑tech innovation enterprises, New productive forces</keywords></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>[1] Cremers M, Pareek A, 2016, Patient Capital Outperformance: The Investment Skill of High Active Share Managers Who Trade Infrequently. Journal of Financial Economics, 122(2): 288&amp;ndash;306.
[2] Deeg R, Hardie I, Maxfield S, 2016, What Is Patient Capital, and Where Does It Exist? Socio-Economic Review, 14(4): 627&amp;ndash;642.
[3] Harrison RT, Botelho T, Mason CM, 2016, Patient Capital in Entrepreneurial Finance: A Reassessment of the Role of Business Angel Investors. Socio-Economic Review, 14(4): 669&amp;ndash;689.
[4] Lerner J, Nanda R, 2020, Venture Capital&amp;rsquo;s Role in Financing Innovation: What We Know and How Much We Still Need to Learn. Journal of Economic Perspectives, 34(3): 237&amp;ndash;261.
[5] Tian X, Wang TY, 2014, Tolerance for Failure and Corporate Innovation. The Review of Financial Studies, 27(1): 211&amp;ndash;255.
[6] Holmstrom B, 1989, Agency Costs and Innovation. Journal of Economic Literature, 27(3): 305&amp;ndash;327.
[7] Li Y, Huang X, Luo H, 2026, Patient Capital and Green Total Factor Productivity: Evidence from Chinese Listed Companies. PLOS ONE, 21(5): e0331262.
[8] Arnold NG, Claveres G, Frie J, 2024, Stepping Up Venture Capital to Finance Innovation in Europe. IMF Working Paper.
[9] OECD, 2025, Venture Capital Investments in Artificial Intelligence Through 2025. OECD AI Policy Observatory.
[10] Hong YX, Jiang JC, 2025, Cultivating and Strengthening Patient Capital to Promote the Development of New Quality Productive Forces. Frontiers of Economics in China, 20(3): 376&amp;ndash;393.
[11] Zhang ZC, Yang AQ, 2025, Patient Capital, Financing Constraints and Enterprise Innovation, Proceedings of the 5th International Conference on Humanities, Social Sciences and Social Research, 412&amp;ndash;418.
[12] Wang Q, 2025, Venture Capital Exit After Venture IPO. Strategic Entrepreneurship Journal, 19(2): 215&amp;ndash;232.
[13] Felix J, Pires S, Gulamhussen MA, 2025, Optimizing Investment Period Length and Strategies for Later Stage Venture Capital Staged Financing Portfolio. Applied Economics, 57(32): 3689&amp;ndash;3706.
[14] Park S, 2025, Patient Capital, Corporate Governance and Investment in Digital Innovation: What Can Japan Learn from South Korea&amp;rsquo;s Experience? Global Policy, 16(2): 189&amp;ndash;204.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
